Clinical trials: Aggressive Behavior
- Condition Aggressive Behavior
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Leukemia, Lymphocytic, Lymphoma
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
- Trial name
- NCT00035022
- Testing
- BCX-1777
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- BioCryst Pharmaceuticals
Substance Use, Stress
Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School
Deviant peer affiliation is one of the most important predictors of alcohol use in adolescence. These affiliations arise when socially marginalized youth self-aggregate and reinforce alcohol use and other deviant activity (i.e.…
- Conditions
- Substance Use, Stress, Relation, Interpersonal, Bullying
- Trial name
- PeerLearning (NCT04478240)
- Testing
- PeerLearning.net
- Where
- United States
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Non-hodgkin Lymphoma
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05206357
- Testing
- Epcoritamab
- Where
- 41 sites in United States, Australia and 12 more
- Volunteers
- 17 people
- Sponsor
- Genmab
Impulsive Aggression Comorbid With ADHD
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
This will be a randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study in children with impulsive aggression comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01364662
- Testing
- SPN-810
- Where
- 27 sites in United States
- Volunteers
- 121 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Prostate Cancer
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
- Trial name
- NCT03256630
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Genomic Health®, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Desmoid Tumor, NOTCH Gene Mutation Positive Tumors
Individual Patient Compassionate Use of Nirogacestat
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Trial name
- NCT05041036
- Testing
- Nirogacestat (Gamma Secretase Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Bullying, Cyberbullying
Using Digital Health Technology to Prevent Bullying and Cyberbullying Among Elementary School Students
This project is designed to address the urgent need for an effective primary prevention approach to the problem of bullying and cyberbullying among elementary school students.
- Conditions
- Bullying, Cyberbullying, Smoking
- Trial name
- NCT06592872
- Testing
- Bullying prevention
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Alzheimer Disease
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
- Trial name
- NCT06875986
- Testing
- Brexpiprazole (Rexulti)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bullying, Cyberbullying
An Evidence-based Approach for Bullying Prevention
This Phase II SBIR project is designed to address the critical public health problem of bullying and cyberbullying among middle school age youth.
- Conditions
- Bullying, Cyberbullying, Substance Use, Substance Abuse
- Trial name
- NCT03205059
- Testing
- LST MS curriculum+ Bullying/Cyberbulling serious game, LST MS curriculum
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Bullying of Child, Bullying
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based Intervention
School interventions to reduce bullying can be effective but also require substantial time and resources. Online technologies have the potential to deliver effective bullying interventions to a large number of middle schools for…
- Trial name
- STAC (NCT04681495)
- Testing
- STAC
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Adolescent, Bullying
Online Bullying Bystander Intervention for Middle Schools Phase II
School interventions to reduce bullying can be effective but also require substantial time and resources. Online technologies have the potential to deliver effective bullying interventions to a large number of middle school…
- Conditions
- Adolescent, Bullying, Technology, Mental Health
- Trial name
- STACII (NCT05572398)
- Testing
- STAC-T
- Where
- 2 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Impulsive Aggression
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
The purpose of this non-interventional study is to optimize the point subtraction aggression paradigms (PSAP) task in typically developing children (TDC).
- Trial name
- NCT03615703
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.